SEARCH

SEARCH BY CITATION

References

  • 1
    Celermajer DS, Sorensen KE, Bull C, Robinson J, Deanfield JE. Endothelium-dependent dilation in the systemic arteries of asymptomatic subjects relates to coronary risk factors and their interaction. J Am Coll Cardiol 1994;24:14681474.
  • 2
    Benjamin EJ, Larson MG, Keyes MJ, et al. Clinical correlates and heritability of flow-mediated dilation in the community: The framingham heart study. Circulation 2004;109:613619.
  • 3
    Corretti MC, Anderson TJ, Benjamin EJ, et al. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: A report of the international brachial artery reactivity task force. J Am Coll Cardiol 2002;39:257265.
  • 4
    Gokce N, Keaney JF, Jr., Hunter LM, et al. Predictive value of noninvasively determined endothelial dysfunction for long-term cardiovascular events in patients with peripheral vascular disease. J Am Coll Cardiol 2003;41:17691775.
  • 5
    Patti G, Pasceri V, Melfi R, et al. Impaired flow-mediated dilation and risk of restenosis in patients undergoing coronary stent implantation. Circulation 2005;111:7075.
  • 6
    Graham IM, Daly LE, Refsum HM, et al. Plasma homocysteine as a risk factor for vascular disease. The European concerted action project. Jama 1997;277:17751781.
  • 7
    Nygard O, Nordrehaug JE, Refsum H, Ueland PM, Farstad M, Vollset SE. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med 1997;337:230236.
  • 8
    Albert CM, Cook NR, Gaziano JM, et al. Effect of folic acid and b vitamins on risk of cardiovascular events and total mortality among women at high risk for cardiovascular disease: A randomized trial. JAMA 2008;299:20272036.
  • 9
    Lonn E, Yusuf S, Arnold MJ, et al. Homocysteine lowering with folic acid and b vitamins in vascular disease. N Engl J Med 2006;354:15671577.
  • 10
    Bonaa KH, Njolstad I, Ueland PM, et al. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med 2006;354:15781588.
  • 11
    Chambers JC, Ueland PM, Obeid OA, Wrigley J, Refsum H, Kooner JS. Improved vascular endothelial function after oral b vitamins: An effect mediated through reduced concentrations of free plasma homocysteine. Circulation 2000;102:24792483.
  • 12
    Mangoni AA, Sherwood RA, Asonganyi B, Swift CG, Thomas S, Jackson SH. Short-term oral folic acid supplementation enhances endothelial function in patients with type 2 diabetes. Am J Hypertens 2005;18:220226.
  • 13
    Schnyder G, Roffi M, Flammer Y, Pin R, Hess OM. Effect of homocysteine-lowering therapy with folic acid, vitamin b12, and vitamin b6 on clinical outcome after percutaneous coronary intervention: The swiss heart study: A randomized controlled trial. Jama 2002;288:973979.
  • 14
    Sydow K, Schwedhelm E, Arakawa N, et al. Adma and oxidative stress are responsible for endothelial dysfunction in hyperhomocyst(e)inemia: Effects of l-arginine and b vitamins. Cardiovasc Res 2003;57:244252.
  • 15
    Title LM, Cummings PM, Giddens K, Genest JJ, Jr., Nassar BA. Effect of folic acid and antioxidant vitamins on endothelial dysfunction in patients with coronary artery disease. J Am Coll Cardiol 2000;36:758765.
  • 16
    Woo KS, Chook P, Chan LL, et al. Long-term improvement in homocysteine levels and arterial endothelial function after 1-year folic acid supplementation. Am J Med 2002;112:535539.
  • 17
    Antoniades C, Antonopoulos AS, Tousoulis D, Marinou K, Stefanadis C. Homocysteine and coronary atherosclerosis: From folate fortification to the recent clinical trials. Eur Heart J 2009;30:615.
  • 18
    Doshi SN, McDowell IF, Moat SJ, et al. Folic acid improves endothelial function in coronary artery disease via mechanisms largely independent of homocysteine lowering. Circulation 2002;105:2226.
  • 19
    Leung WH, Lau CP, Wong CK. Beneficial effect of cholesterol-lowering therapy on coronary endothelium-dependent relaxation in hypercholesterolaemic patients. Lancet 1993;341:14961500.
  • 20
    John S, Schneider MP, Delles C, Jacobi J, Schmieder RE. Lipid-independent effects of statins on endothelial function and bioavailability of nitric oxide in hypercholesterolemic patients. Am Heart J 2005;149:473.
  • 21
    Beckman JA, Liao JK, Hurley S, et al. Atorvastatin restores endothelial function in normocholesterolemic smokers independent of changes in low-density lipoprotein. Circ Res 2004;95:217223.
  • 22
    Vita JA, Gokce N, Duffy SJ, et al. Effect of atorvastatin on endothelium-dependent vasodilation in patients with coronary artery disease. Am J Cardiol 2003;91:857860.
  • 23
    Gounari P, Tousoulis D, Antoniades C, et al. Rosuvastatin but not ezetimibe improves endothelial function in patients with heart failure, by mechanisms independent of lipid lowering. Int J Cardiol 2010;142:8791.
  • 24
    Landmesser U, Bahlmann F, Mueller M, et al. Simvastatin versus ezetimibe: Pleiotropic and lipid-lowering effects on endothelial function in humans. Circulation 2005;111:23562363.
  • 25
    Leung WH, Lau CP, Wong CK.Beneficial effect of cholesterol-lowering therapy on coronary endothelium-dependent relaxation in hypercholesterolaemic patients. The Lancet 1993;341:14961500.
  • 26
    Ray KK, Cannon CP.The potential relevance of the multiple lipid-independent (pleiotropic) effects of statins in the management of acute coronary syndromes. J Am Coll Cardiol 2005;46:14251433.
  • 27
    Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated c-reactive protein. N Engl J Med 2008;359:21952207.
  • 28
    Laufs U, Gertz K, Dirnagl U, Bohm M, Nickenig G, Endres M: Rosuvastatin, a new HMG-CoA reductase inhibitor, upregulates endothelial nitric oxide synthase and protects from ischemic stroke in mice. Brain Res 2002;942:2330.
  • 29
    Cominacini L, Pasini AF, Garbin U, et al. Oxidized low density lipoprotein (ox-LDL) binding to ox-LDL receptor-1 in endothelial cells induces the activation of nf-kappab through an increased production of intracellular reactive oxygen species. J Biol Chem 2000;275:1263312638.
  • 30
    Cominacini L, Anselmi M, Garbin U, et al. Enhanced plasma levels of oxidized low-density lipoprotein increase circulating nuclear factor-kappa b activation in patients with unstable angina. J Am Coll Cardiol 2005;46:799806.
  • 31
    Shirodaria C, Antoniades C, Lee J, et al. Global improvement of vascular function and redox state with low-dose folic acid: Implications for folate therapy in patients with coronary artery disease. Circulation 2007;115:22622270.
  • 32
    Antoniades C, Shirodaria C, Warrick N, et al. 5-methyltetrahydrofolate rapidly improves endothelial function and decreases superoxide production in human vessels: Effects on vascular tetrahydrobiopterin availability and endothelial nitric oxide synthase coupling. Circulation 2006;114:11931201.
  • 33
    Title LM, Ur E, Giddens K, McQueen MJ, Nassar BA.Folic acid improves endothelial dysfunction in type 2 diabetes—an effect independent of homocysteine-lowering. Vasc Med 2006;11:101109.
  • 34
    Ferretti G, Bacchetti T, Moroni C, Vignini A, Nanetti L, Curatola G.Effect of homocysteinylation of low density lipoproteins on lipid peroxidation of human endothelial cells. J Cell Biochem 2004;92:351360.
  • 35
    Heinecke JW. Oxidants and antioxidants in the pathogenesis of atherosclerosis: Implications for the oxidized low density lipoprotein hypothesis. Atherosclerosis 1998;141:115.